Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer Research… — JAMA (Journal of the American Medical Association)

JAMA (Journal of the American Medical Association)@jamaupdates · 16.8K subscribers Open in TelegramOpen

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2855790

This trial compared trastuzumab rezetecan vs physician’s choice of chemotherapy in patients with erythroblastic oncogene B (ERBB2)–low metastatic breast cancer.

t.me/jamaupdates/6788

October 23, 2026 736 1